COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 186 participants.
Also called NCT07245680
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 186 participants
- Registry
-
NCT07245680 -
2023-509891-40-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT07245680. Randomized; triple masking; primary purpose treatment. Start 2026-04-28 (actual); primary completion 2029-02-14 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities
- Acronym
- COMMODITIES
- Condition
- Pulmonary Arterial Hypertension (PAH)
- Condition
- Comorbidities
- Condition
- Cardiovascular Disease (CVD)
- Intervention (Drug)
- Tadalafil
- Intervention (Drug)
- Ambrisentan
- Intervention (Drug)
- Placebo (Ambrisentan-matching)
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
Record details
- Record id
cardio:ct-nct07245680- Content hash
469d1197d0f345244391a8ec99e1053b55123ba0d9f1abb3756a0cb8aef22181